ADPT — Adaptive Biotechnologies Corporation

Summary of Adaptive Biotechnologies Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $94 million, a 102% increase year-over-year.
• MRD Revenue: $56.8 million, up 52% year-over-year, with clinical and pharma contributing 67% and 33%, respectively.
• Adjusted EBITDA: $28 million, compared to a loss of $14.3 million in the previous year.
• Net Income: $9.5 million for the quarter.
• Gross Margin: Total company gross margin was 70%, with sequencing gross margin at 66%, up from 56% a year ago.
• Cash Position: Ended the quarter with $217 million in cash, with a 51% reduction in cash burn year-to-date.

2. Strategic Updates and Business Highlights:

• MRD Business Growth: Achieved cash flow positivity and adjusted EBITDA of $7 million. Clinical volume increased significantly, with over 27,100 tests delivered, a 38% increase year-over-year.
• Clinical Validation: Updates to NCCN guidelines support MRD testing, enhancing clinical utility and integration into patient care.
• EMR Integrations: Continued progress in EMR integrations, with 11 new integrations completed, leading to increased testing volumes and improved operational efficiencies.
• MRD Pharma Business: Revenue grew 11% year-over-year, with a backlog exceeding $200 million, reflecting strong partner demand.

3. Forward Guidance and Outlook:

• Updated Full-Year Guidance: MRD revenue guidance raised to $202 million to $207 million, up from $190 million to $200 million. Expected to deliver approximately 104,000 tests for the year.
• Operating Expense Guidance: Tightened to $335 million to $340 million, down from $335 million to $345 million.
• Cash Burn Guidance: Narrowed to $45 million to $50 million, driven by higher MRD revenue.

4. Bad News, Challenges, or Points of Concern:

• Competition: Emerging competition in DLBCL could pose challenges, although Adaptive maintains a strong market position.
• Regulatory Uncertainty: Recent agency news regarding surrogate endpoints introduces some uncertainty in the MRD Pharma space.
• Seasonality: Anticipated seasonality in Q4 may impact revenue growth, as holiday periods can affect ordering patterns.

5. Notable Q&A Insights:

• MRD Pharma Backlog: Management indicated that the $200 million backlog will be recognized over a 5 to 7-year timeframe, with expectations of continued growth in 2026.
• ASP Growth: Confidence in achieving long-term ASP targets of $1,700 to $1,800 per test, with current ASP at $1,340.
• Community Penetration: Community settings now account for 30% of volume, with ongoing efforts to increase penetration and utilization of clonoSEQ.
• EMR Tools: New tools in EMR systems allow for serial testing orders, which may enhance testing frequency and patient management.
• Guideline Impact: Recent guideline updates are beginning to influence clinical uptake, particularly in multiple myeloma and CLL, with ongoing education efforts to support adoption.

Overall, Adaptive Biotechnologies reported strong financial performance and strategic advancements in its MRD business, while also navigating competitive pressures and regulatory uncertainties. The company remains optimistic about future growth and operational efficiencies.